Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Allopurinol sodium

Phase 3Small molecule

Allopurinol sodium is one of 2 small molecule programs targeting Fetal Hypoxia. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fetal HypoxiaActive, not recruiting

Fetal HypoxiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Fetal Hypoxia

#DrugCompanyPhaseTrials

Osmitrol

BB. Braun Medical Inc.

Allopurinol sodium

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fetal Hypoxia1 trial

Antenatal Allopurinol During Fetal Hypoxia

Unknown status·UUMC Utrecht·Phase 3·NCT00189007·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Allopurinol sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allopurinol sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allopurinol sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UMC Utrecht company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUMC Utrecht

Related News